

# Bo Xu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2952992/publications.pdf>

Version: 2024-02-01

234  
papers

4,639  
citations

136950

32  
h-index

144013

57  
g-index

235  
all docs

235  
docs citations

235  
times ranked

4219  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Predictors, and Impact of Coronary Artery Ectasia in Patients With Atherosclerotic Heart Disease. <i>Angiology</i> , 2023, 74, 47-54.	1.8	3
2	Differential impact of abluminal <scp>grooveâ€filled biodegradableâ€polymer sirolimusâ€eluting</scp> stent versus <scp>durableâ€polymer everolimusâ€eluting</scp> stent on and off dual antiplatelet therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 357-365.	1.7	1
3	The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 812-820.	4.0	6
4	Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, .	1.7	9
5	Outcomes of successful vs. failed contemporary chronic total occlusion percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2022, 37, 483-489.	2.3	5
6	Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12â€Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-15.	1.2	0
7	Validation of the Vâ€RESOLVE (Visual Estimation for Risk prEdiction of Side Branch Occlusion) in Tj ETQq1 1 0.784314 rgBT /Overloc <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1465-1472.	1.7	4
8	Longâ€term prognostic value of dynamic function assessment of intermediate coronary lesion with computational physiology. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1386-1394.	1.7	1
9	Long-term safety and absorption assessment of a novel bioresorbable nitrided iron scaffold in porcine coronary artery. <i>Bioactive Materials</i> , 2022, 17, 496-505.	15.6	16
10	Post-PCI outcomes predicted by pre-intervention simulation of residual quantitative flow ratio using augmented reality. <i>International Journal of Cardiology</i> , 2022, 352, 33-39.	1.7	15
11	Automatic construction of coronary artery tree structure based on vessel blood flow tracking. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	0
12	Protective ballooning technique for prevention of side branch occlusion in coronary nonleft main true bifurcation lesions: A singleâ€center study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	1
13	Evaluation of the effect of simultaneous hybrid coronary revascularization on postoperative bleeding and renal function: A comparison study with minimally invasive direct off-pump coronary artery bypass grafting in patients with multivessel coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.8	1
14	Outcomes of quantitative flow ratio-based percutaneous coronary intervention in an all-comers study. <i>EuroIntervention</i> , 2022, 17, 1240-1251.	3.2	10
15	Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011312.	3.9	8
16	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. <i>Cardiovascular Diabetology</i> , 2022, 21, 46.	6.8	27
17	Effects of diabetes mellitus on post-intervention coronary physiological assessment derived by quantitative flow ratio in patients with coronary artery disease underwent percutaneous coronary intervention. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109839.	2.8	10
18	Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210817.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Response by Lin et al to Letter Regarding Article, "Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease": Circulation: Cardiovascular Interventions, 2022, 15, e012099.	3.9	0
20	New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011536.	3.9	12
21	Prognostic Implications of Pre-stent Pullback Pressure Gradient and Post-stent Quantitative Flow Ratio in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, .	3.7	6
22	Angiographic Lesion Morphology Provides Incremental Value to Generalize Quantitative Flow Ratio for Predicting Myocardial Ischemia. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	1
23	Resting distal to aortic pressure ratio and fractional flow reserve discordance affects the diagnostic performance of quantitative flow ratio: Results from an individual patient data meta-analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 825-832.	1.7	1
24	Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion. European Journal of Clinical Investigation, 2021, 51, e13368.	3.4	3
25	Impact of public health emergency response to COVID-19 on management and outcome for NSTEMI patients in Beijing: A single-center historic control. Catheterization and Cardiovascular Interventions, 2021, 97, E475-E483.	1.7	5
26	Association of <i>NPC1L1</i> and <i>HMGCR</i> Gene Polymorphisms with Major Adverse Cardiac and Cerebrovascular Events in Patients with Three-Vessel Disease. Human Gene Therapy, 2021, 32, 581-588.	2.7	5
27	Short- and long-term functional results following drug-coated balloons versus drug-eluting stents in small coronary vessels: The RESTORE quantitative flow ratio study. International Journal of Cardiology, 2021, 327, 45-51.	1.7	3
28	Body mass index and mortality in patients with severe coronary artery diseases: A cohort study from China. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 448-454.	2.6	7
29	Long-Term Clinical Outcomes of Unprotected Left Main Percutaneous Coronary Intervention: A Large Single-Centre Experience. Journal of Interventional Cardiology, 2021, 2021, 1-10.	1.2	6
30	Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China. Cardiovascular Diabetology, 2021, 20, 16.	6.8	7
31	Long-Term Outcomes of Single-Vessel Percutaneous Coronary Intervention on Culprit Vessel vs. Multivessel Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Multivessel Coronary Artery Disease. Circulation Journal, 2021, 85, 185-193.	1.6	1
32	Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC: Cardiovascular Interventions, 2021, 14, 278-288.	2.9	22
33	Predicting 2-year all-cause mortality after contemporary <i>PCI</i> : Updating the logistic clinical <i>SYNTAX</i> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
34	Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheterization and Cardiovascular Interventions, 2021, 97, 976-981.	1.7	8
35	<i>External</i> carotid artery stenting in patients with ipsilateral internal carotid artery occlusion: Peri-operative and 12-month follow-up. Catheterization and Cardiovascular Interventions, 2021, 97, 982-987.	1.7	2
36	<i>Nine-month</i> angiographic and <i>2-year</i> clinical outcomes of the <i>RECOVERY</i> trial: A randomized study of the biodegradable polymer <i>sirolimus-eluting COMBO dual-therapy</i> stent versus a <i>polymer-free sirolimus-eluting</i> stent in Chinese patients. Catheterization and Cardiovascular Interventions, 2021, 97, 966-975.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Accuracy of Intravascular Ultrasound-Based Fractional Flow Reserve in Identifying Hemodynamic Significance of Coronary Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009840.	3.9	41
38	Angiographic characteristics and long-term outcomes of single-vessel chronic total occlusion percutaneous coronary intervention in patients with and without previous myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1089-1096.	1.7	0
39	Thirty-day and 5-year results of percutaneous coronary intervention for in-stent restenotic chronic total occlusion lesions: Data from 2,659 consecutive patients. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1016-1024.	1.7	3
40	Long-term clinical outcomes in transradial versus transfemoral access for left main percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1009-1015.	1.7	0
41	Association of symptom status, myocardial viability, and clinical/anatomic risk on long-term outcomes after chronic total occlusion percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 996-1008.	1.7	3
42	Diagnostic accuracy of quantitative flow ratio for assessment of coronary stenosis significance from a single angiographic view: A novel method based on bifurcation fractal law. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1040-1047.	1.7	94
43	Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	3
44	Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions. <i>European Heart Journal</i> , 2021, 42, 2695-2707.	2.2	34
45	Scanning Electron Microscopic Assessment of Stent Coating Integrity in Jailed Wire Technique for Bifurcation Treatment. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-5.	1.2	2
46	Intravascular ultrasound and ultrasonic flow ratio-guided zero-contrast percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, .	0.7	0
47	CT-FFR vs a model of combined plaque characteristics for identifying ischemia: Results from CT-FFR CHINA trial. <i>European Journal of Radiology</i> , 2021, 138, 109634.	2.6	6
48	Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1450-1462.	2.9	10
49	Training and validation of a deep learning architecture for the automatic analysis of coronary angiography. <i>EuroIntervention</i> , 2021, 17, 32-40.	3.2	33
50	Variation of computed tomographic angiography-based fractional flow reserve after transcatheter aortic valve implantation. <i>European Radiology</i> , 2021, 31, 6220-6229.	4.5	1
51	Prognosis of spontaneous myocardial infarction and various definitions of periprocedural myocardial infarction in patients who underwent percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2021, 333, 60-68.	1.7	3
52	PDLLA-Zn-nitrided Fe bioresorbable scaffold with 53- $\frac{1}{4}$ m-thick metallic struts and tunable multistage biodegradation function. <i>Science Advances</i> , 2021, 7, .	10.3	31
53	CYP2C19 genotype has prognostic value in specific populations following coronary stenting. <i>Annals of Translational Medicine</i> , 2021, 9, 1066-1066.	1.7	4
54	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 143.	6.8	22

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 873-882.	2.0	7
56	The Predictive Value of Baseline Target Lesion SYNTAX Score for No-Reflow during Urgent Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-9.	1.2	3
57	5-Year Clinical Outcomes of Successful Recanalisation for Coronary Chronic Total Occlusions in Patients With or Without Type 2 Diabetes Mellitus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691641.	2.4	2
58	Direct Bilirubin Levels Predict Long-Term Outcomes in Patients With Acute Coronary Syndrome Under Different Glucose Metabolism Status: A 6.5-Year Cohort Study of Three-Vessel Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715539.	2.4	2
59	Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1623-1634.	2.9	27
60	Global Chronic Total Occlusion Crossing Algorithm. <i>Journal of the American College of Cardiology</i> , 2021, 78, 840-853.	2.8	111
61	No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1120-1129.	1.6	47
62	Effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome. <i>World Journal of Emergency Medicine</i> , 2021, 12, 36.	1.0	6
63	Impact of Periprocedural Myocardial Injury and Infarction Definitions on Long-Term Mortality After Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010923.	3.9	3
64	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 736466.	2.4	6
65	Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study. <i>Frontiers in Neurology</i> , 2021, 12, 740136.	2.4	2
66	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. <i>Lancet</i> , The, 2021, 398, 2149-2159.	13.7	175
67	Comparison of outcomes for percutaneous coronary intervention in men and women with unprotected left main disease. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 168-174.	0.2	1
68	Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Annals of Medicine</i> , 2021, 53, 2217-2226.	3.8	1
69	Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768190.	2.4	4
70	Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 704501.	2.4	5
71	Effect of Coronary Calcification Severity on Measurements and Diagnostic Performance of CT-FFR With Computational Fluid Dynamics: Results From CT-FFR CHINA Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 810625.	2.4	3
72	Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Global Heart</i> , 2021, 16, 89.	2.3	2

#	ARTICLE	IF	CITATIONS
73	Does Percutaneous Coronary Intervention on Off Days have an Effect on Long-term Prognosis in Patients with Coronary Artery Disease in China?. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 387-394.	0.2	0
74	Two-year safety evaluation of a biodegradable polymer sirolimus-eluting stent with increased drug elution and polymer absorption kinetics in complex patient and lesion cohort. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 206-215.	1.7	3
75	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
76	First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE): Three-year clinical and imaging outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 648-657.	1.7	11
77	A modified predilation, sizing, and postdilation scoring system for patients undergoing metallic drug-eluting stent implantations. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 558-564.	1.7	1
78	Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation. <i>European Heart Journal</i> , 2020, 41, 3271-3279.	2.2	69
79	Impact of unknown diabetes and prediabetes on clinical outcomes in non-diabetic Chinese patients after a primary coronary intervention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 644-651.	2.6	8
80	The effect of stenting on blood pressure in hypertensive patients with symptomatic proximal subclavian or vertebral artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 633-640.	1.7	1
81	Integrating the residual SYNTAX score to improve the predictive ability of the age, creatinine, and ejection fraction (ACEF) score for cardiac mortality in percutaneous coronary intervention patients. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 534-541.	1.7	6
82	Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 265-273.	2.6	17
83	Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 528-533.	1.6	8
84	Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1023-1028.	1.7	3
85	Prognostic Value of Quantitative Flow Ratio Based Functional SYNTAX Score in Patients With Left Main or Multivessel Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009155.	3.9	19
86	Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. <i>Chinese Medical Journal</i> , 2020, 133, 2674-2681.	2.3	3
87	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1617-1638.	2.9	60
88	Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 133, 61-70.	1.6	5
89	Prognostic significance of occlusion length in recanalized chronic total occlusion lesion: a retrospective cohort study with 5-year follow-up. <i>BMJ Open</i> , 2020, 10, e038302.	1.9	5
90	Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2020, 36, 1739-1745.	1.9	10

#	ARTICLE	IF	CITATIONS
91	Feasibility of using deep learning to detect coronary artery disease based on facial photo. <i>European Heart Journal</i> , 2020, 41, 4400-4411.	2.2	67
92	Active SB-P Versus Conventional Approach to the Protection of High-Risk Side Branches. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1112-1122.	2.9	11
93	Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-10.	1.2	7
94	Long-Term Clinical Outcomes for Non-ST Elevation Acute Coronary Syndrome Patients with High-Risk Angiographic Findings Undergoing Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	1.2	0
95	Mis-estimation of coronary lesions and rectification by SYNTAX score feedback for coronary revascularization appropriateness. <i>Chinese Medical Journal</i> , 2020, 133, 1276-1284.	2.3	1
96	CCI and CIT 2020 – A special year of the special issue. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 532-533.	1.7	0
97	D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232090430.	2.5	18
98	Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions. <i>Scientific Reports</i> , 2020, 10, 10461.	3.3	12
99	Quantitative flow ratio – guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial. <i>American Heart Journal</i> , 2020, 223, 72-80.	2.7	34
100	Effect of Lifestyle Changes after Percutaneous Coronary Intervention on Revascularization. <i>BioMed Research International</i> , 2020, 2020, 1-6.	1.9	2
101	Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 587-597.	1.7	19
102	Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 550-557.	1.7	2
103	Percutaneous transluminal angioplasty with selective stenting for the treatment of renal artery stenosis caused by fibromuscular dysplasia: 18 years' experience from the China Center for Cardiovascular Disease. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 641-647.	1.7	8
104	Association of $\beta$ -Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-10.	2.5	5
105	Two-Year Outcomes after Left Main Coronary Artery Percutaneous Coronary Intervention in Patients Presenting with Acute Coronary Syndrome. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-8.	1.2	3
106	Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. <i>Frontiers in Endocrinology</i> , 2020, 11, 603922.	3.5	5
107	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
108	Reproducibility of quantitative flow ratio: An inter-core laboratory variability study. <i>Cardiology Journal</i> , 2020, 27, 230-237.	1.2	14

#	ARTICLE	IF	CITATIONS
109	Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. <i>Cardiology Journal</i> , 2020, 27, 350-361.	1.2	36
110	Validation of the long-term prognostic capability of the SYNTAX score II in patients undergoing biodegradable polymer-based Sirolimus-eluting stents: 2-year outcomes from the PANDA III trial. <i>International Journal of Cardiology</i> , 2020, 309, 27-32.	1.7	3
111	Contrast Induced Nephropathy and 2-Year Outcomes of Iso-Osmolar Compared with Low-Osmolar Contrast Media after Elective Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2020, 51, 174.	1.9	9
112	Risk or Beneficial Factors Associated with Unplanned Revascularization Risk Following Percutaneous Coronary Intervention: A Large Single-Center Data. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 431-443.	0.2	1
113	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 420-433.	1.6	263
114	Prognostic Significance of In-hospital Acquired Thrombocytopenia in Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of the Medical Sciences</i> , 2019, 358, 19-25.	1.1	3
115	Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 245-255.	2.9	31
116	Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985363.	1.7	3
117	Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. <i>European Heart Journal</i> , 2019, 40, 3397-3405.	2.2	39
118	Association of Baseline Smoking Status with Long-Term Prognosis in Patients Who Underwent Percutaneous Coronary Intervention: Large Single-Center Data. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-9.	1.2	4
119	2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1679-1687.	2.9	14
120	Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 832-838.	1.7	12
121	Prognostic Value of Plasma Big Endothelin-1 Level among Patients with Three-Vessel Disease: A Cohort Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 959-969.	2.0	9
122	Validating the Performance of 5 Risk Scores for Major Adverse Cardiac Events in Patients Who Achieved Complete Revascularization After Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1058-1068.	1.7	9
123	Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patient data meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 693-701.	1.7	79
124	Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 872-882.	1.8	31
125	Accuracy of 3-dimensional and 2-dimensional quantitative coronary angiography for predicting physiological significance of coronary stenosis: a FAVOR II substudy. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 481-491.	1.7	7
126	Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention. <i>Chinese Medical Journal</i> , 2019, 132, 914-921.	2.3	9



#	ARTICLE	IF	CITATIONS
127	Long-term outcomes of percutaneous coronary intervention in grafts and native vessels in coronary artery bypass grafting patients with diabetes mellitus. <i>Journal of Thoracic Disease</i> , 2019, 11, 4798-4806.	1.4	4
128	Impact of baseline thrombocytopenia on the long-term outcome of patients undergoing elective percutaneous coronary intervention: An analysis of 9,897 consecutive patients. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 764-771.	1.7	7
129	Is the SYNTAX Score II applicable in all percutaneous coronary intervention patients?. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 779-786.	1.7	4
130	Safety and feasibility of simultaneous endovascular therapy for supra-arch multivessel stenosis in 256 Chinese patients. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 846-850.	1.7	1
131	Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 818-824.	1.7	5
132	Effect of prior stroke on long-term outcomes of percutaneous coronary interventions in Chinese patients: A large single-center study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E75-E80.	1.7	3
133	Automatic coronary blood flow computation: validation in quantitative flow ratio from coronary angiography. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 587-595.	1.5	16
134	Implications of Hyperuricemia in Severe Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2019, 123, 558-564.	1.6	14
135	Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention. <i>Cardiology Journal</i> , 2019, 26, 138-146.	1.2	10
136	A Propensity Score Matching Analysis of Transradial Versus Transfemoral Approaches in Octogenarians Undergoing Percutaneous Coronary Intervention. <i>Acta Cardiologica Sinica</i> , 2019, 35, 301-307.	0.2	5
137	Prognostic Values of Serum Chloride and Sodium Levels in Patients with Three-vessel Disease. <i>Biomedical and Environmental Sciences</i> , 2019, 32, 250-259.	0.2	2
138	Analysis of anomalous origin of coronary arteries by coronary angiography in Chinese patients with coronary artery disease. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1331-1337.	1.5	2
139	One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the <i>NeoVas</i> sirolimus-eluting scaffold in patients with single de novo coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 617-622.	1.7	6
140	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. <i>Circulation</i> , 2018, 137, 2231-2245.	1.6	68
141	Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. <i>JAMA Internal Medicine</i> , 2018, 178, 239.	5.1	34
142	A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 260-272.	2.9	35
143	Validation of the <i>RESOLVE</i> visual estimation for <i>RISK</i> Tj ETQq1 1 0.784314 rgBT /Overlap and Cardiovascular Interventions. 2018, 91, 591-598.	1.7	10
144	Carotid artery stenting followed by open heart surgery in 323 patients: One-year results and influencing factors. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 632-638.	1.7	6

#	ARTICLE	IF	CITATIONS
145	Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 551-557.	1.7	30
146	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 573-581.	1.7	21
147	Proximal left anterior descending coronary artery stenosis should be considered when using the prognostic value of the residual SYNTAX score: Data from 10343 consecutive patients with long-term follow up in the real world. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 639-645.	1.7	2
148	Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve. <i>Structural Heart</i> , 2018, 2, 60-68.	0.6	18
149	Sex-based differences in bleeding and long-term adverse events after percutaneous coronary intervention in older patients with coronary artery disease. <i>Journal of Interventional Cardiology</i> , 2018, 31, 345-352.	1.2	4
150	Impact of Diabetes Mellitus on Percutaneous Coronary Intervention in Chinese Patients: A Large Single-Center Data. <i>Angiology</i> , 2018, 69, 540-547.	1.8	11
151	Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina) on outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Interventional Cardiology</i> , 2018, 31, 5-14.	1.2	17
152	Usefulness of the SYNTAX score II to validate 2-year outcomes in patients with complex coronary artery disease undergoing percutaneous coronary intervention: A large single-center study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 40-47.	1.7	15
153	Real-time Lesion Detection of Cardiac Coronary Artery Using Deep Neural Networks. , 2018, , .		7
154	Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. <i>Chinese Medical Journal</i> , 2018, 131, 1397-1405.	2.3	0
155	Impact of Residual SYNTAX Score and Its Derived Indexes on Clinical Outcomes after Percutaneous Coronary Intervention. <i>Chinese Medical Journal</i> , 2018, 131, 1390-1396.	2.3	3
156	Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention. <i>Chinese Medical Journal</i> , 2018, 131, 2699-2704.	2.3	8
157	Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. <i>Chinese Medical Journal</i> , 2018, 131, 1406-1411.	2.3	4
158	Impact of anemia on percutaneous coronary intervention in Chinese patients: A large single center data. <i>Journal of Interventional Cardiology</i> , 2018, 31, 826-833.	1.2	8
159	Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2381-2392.	2.9	81
160	Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2368-2377.	2.9	26
161	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1117-1126.	13.7	46
162	Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. <i>Chinese Medical Journal</i> , 2018, 131, 262-267.	2.3	3

#	ARTICLE	IF	CITATIONS
163	Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 122, 2043-2048.	1.6	15
164	A Comparison of Transradial and Transfemoral Percutaneous Coronary Intervention in Chinese Women Based on a Propensity Score Analysis. <i>Korean Circulation Journal</i> , 2018, 48, 719.	1.9	3
165	Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. <i>Cardiovascular Diabetology</i> , 2018, 17, 114.	6.8	8
166	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. <i>European Heart Journal</i> , 2018, 39, 3314-3321.	2.2	116
167	Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy. <i>International Urology and Nephrology</i> , 2018, 50, 1879-1886.	1.4	4
168	Effect of PEAR1 Genetic Variants on 1-Year Outcomes in Chinese Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 454-459.	2.0	9
169	Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial. <i>EuroIntervention</i> , 2018, 14, e554-e561.	3.2	25
170	The effectiveness and safety of the RESTORE drug-eluting balloon versus a drug-eluting stent for small coronary vessel disease: study protocol for a multi-center, randomized, controlled trial. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 469-475.	0.2	2
171	Prognostic Value of NT-proBNP in Stable Coronary Artery Disease in Chinese Patients after Percutaneous Coronary Intervention in the Drug-eluting Stent Era. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 859-866.	0.2	5
172	5-Year Safety and Efficacy of Resolute-Zotarolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 247-254.	2.9	25
173	Difference of coronary stenosis severity between systolic and diastolic phases in quantitative CT angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 105-110.	1.3	5
174	Comparison of two biodegradable polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 520-527.	1.7	3
175	Impact of completeness of revascularization in complex coronary artery disease as measured with the SYNTAX revascularization index: An SEEDS Substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 541-548.	1.7	5
176	Endovascular therapy for AngioSeal <sup>TM</sup> -related acute limb ischemia: Perioperative and long-term results. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 609-615.	1.7	1
177	Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large single-center data. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12271.	2.5	7
178	Comparison of Transradial and Transfemoral Approaches in Women Undergoing Percutaneous Coronary Intervention in China: A Retrospective Observational Study. <i>Angiology</i> , 2017, 68, 799-806.	1.8	8
179	Prognostic Value of the Clinical SYNTAX Score on 2-Year Outcomes in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 1493-1499.	1.6	12
180	Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the LOVE-T 2 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 555-564.	1.7	8

#	ARTICLE	IF	CITATIONS
181	Effect of coronary dominance on 2-year outcomes after percutaneous coronary intervention in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 549-554.	1.7	4
182	Updated evidence for left main coronary artery disease: Practice versus the consensus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 312-313.	0.8	3
183	Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3077-3087.	2.8	355
184	Plasma big endothelin-1 and stent thrombosis: An observational study in patients undergoing percutaneous coronary intervention in China. <i>Thrombosis Research</i> , 2017, 159, 5-12.	1.7	8
185	Intravascular Ultrasound Guidance Improves the Long-term Prognosis in Patients with Unprotected Left Main Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Scientific Reports</i> , 2017, 7, 2377.	3.3	23
186	Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis. <i>Chinese Medical Journal</i> , 2017, 130, 929-935.	2.3	6
187	Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early period of acute coronary syndrome are derived from peripheral blood mononuclear cells. <i>PLoS ONE</i> , 2017, 12, e0184256.	2.5	25
188	Impact of residual SYNTAX score on clinical outcomes after incomplete revascularisation percutaneous coronary intervention: a large single-centre study. <i>EuroIntervention</i> , 2017, 13, 1185-1193.	3.2	18
189	Effect of residual SYNTAX score on clinical outcomes after incomplete revascularisation percutaneous coronary intervention: a large single-centre study. <i>Chinese Medical Sciences Journal</i> , 2017, 32, 161-170.		
190	An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 83-87.	0.8	5
191	The interval between carotid artery stenting and open heart surgery is related to perioperative complications. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 564-569.	1.7	2
192	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2249-2258.	2.8	40
193	One-stop hybrid coronary revascularization versus off-pump coronary artery bypass in patients with diabetes mellitus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 1695-1701.e1.	0.8	26
194	Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	30
195	Plasma endothelin-1 level as a predictor for poor collaterals in patients with ≥95% coronary chronic occlusion. <i>Thrombosis Research</i> , 2016, 142, 21-25.	1.7	7
196	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. <i>Thrombosis Research</i> , 2016, 147, 108-114.	1.7	10
197	Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2086-2093.	2.9	97
198	Two-year results and subgroup analyses of the PISCES China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 624-629.	1.7	34

#	ARTICLE	IF	CITATIONS
199	Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1102-1111.	2.9	42
200	Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. <i>Thrombosis Research</i> , 2016, 141, 28-34.	1.7	26
201	Simultaneous Bilateral vs Unilateral Carotid Artery Stenting. <i>Journal of Endovascular Therapy</i> , 2016, 23, 258-266.	1.5	9
202	Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. <i>Platelets</i> , 2016, 27, 75-79.	2.3	17
203	Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Two-year results from a prospective patient-level pooled analysis of TARGET trials. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 734-743.	1.7	10
204	A glance at clinical research in interventional cardiology presented to CIT 2015. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 694-695.	1.7	0
205	Clinical and Angiographic Predictors of Major Side Branch Occlusion after Main Vessel Stenting in Coronary Bifurcation Lesions. <i>Chinese Medical Journal</i> , 2015, 128, 1471-1478.	2.3	12
206	An Angiographic Tool for Risk Prediction of Side Branch Occlusion in Coronary Bifurcation Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 39-46.	2.9	74
207	Relationship of High-Density Lipoprotein Cholesterol With Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention in Patients With Low-Density Lipoprotein Cholesterol Below 70 mg/dL. <i>Journal of the American Heart Association</i> , 2015, 4, e001412.	3.7	18
208	Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 536-546.	2.9	101
209	Comparison between one-stent versus two-stent technique for treatment of left main bifurcation lesions: A large single-center data. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1132-1138.	1.7	22
210	How bifurcation angle impacts the fate of side branch after main vessel stenting: A retrospective analysis of 1,200 consecutive bifurcation lesions in a single center. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 706-715.	1.7	28
211	Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2298-2309.	2.8	228
212	A Comparison of Transradial and Transfemoral Approaches for Percutaneous Coronary Intervention in Elderly Patients Based on a Propensity Score Analysis. <i>Angiology</i> , 2015, 66, 448-455.	1.8	8
213	Comparison of Short- and Medium-Term Clinical Outcomes between Transradial Approach and Transfemoral Approach in a High-Volume PCI Heart Center in China. <i>PLoS ONE</i> , 2015, 10, e0118491.	2.5	5
214	Plasma miR-122 and miR-3149 Potentially Novel Biomarkers for Acute Coronary Syndrome. <i>PLoS ONE</i> , 2015, 10, e0125430.	2.5	37
215	Left atrial appendage closure monitoring without sedation: a pilot study using intracardiac echocardiography through the oesophageal route. <i>EuroIntervention</i> , 2015, 11, 936-941.	3.2	29
216	Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e101719.	2.5	6

#	ARTICLE	IF	CITATIONS
217	Is Being an Elderly Woman a Risk Factor for Worse Outcomes After Percutaneous Coronary Intervention? A Large Cohort Study From One Center. <i>Angiology</i> , 2014, 65, 596-601.	1.8	1
218	Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2014, 8, 423-432.	1.5	12
219	The Ratio of High-Density Lipoprotein Cholesterol to Apolipoprotein A Predicts Myocardial Injury Following Elective Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2014, 37, 558-565.	1.8	7
220	Relationship Between ABCB1 Polymorphisms, Thromboelastography and Risk of Bleeding Events in Clopidogrel-Treated Patients With ST-Elevation Myocardial Infarction. <i>Thrombosis Research</i> , 2014, 134, 970-975.	1.7	25
221	Effect of one-stop hybrid coronary revascularization on postoperative renal function and bleeding: A comparison study with off-pump coronary artery bypass grafting surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1511-1516.e1.	0.8	29
222	One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience. <i>Chinese Medical Journal</i> , 2014, 127, 1003-7.	2.3	1
223	Bioresorbable scaffolds for coronary artery disease: current status and future prospective. <i>Chinese Medical Journal</i> , 2014, 127, 1141-8.	2.3	1
224	Long-term outcomes of complete versus incomplete revascularization after drug-eluting stent implantation in patients with multivessel coronary disease. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 343-349.	1.7	21
225	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. <i>EuroIntervention</i> , 2013, 9, 75-83.	3.2	60
226	LONG-TERM OUTCOMES OF COMPLETE VERSUS INCOMPLETE REVASCULARISATION AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH MULTIVESSEL CORONARY DISEASE. <i>Heart</i> , 2012, 98, E158.2-E158.	2.9	0
227	Atorvastatin Accelerates Both Neointimal Coverage and Re-Endothelialization After Sirolimus-Eluting Stent Implantation in a Porcine Model. <i>Circulation Journal</i> , 2012, 76, 2561-2571.	1.6	28
228	Smoking Status on Outcomes After Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2012, 35, 570-574.	1.8	24
229	Transradial Versus Transfemoral Method of Percutaneous Coronary Revascularization for Unprotected Left Main Coronary Artery Disease: Comparison of Procedural and Late-Term Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1035-1042.	2.9	52
230	Prevalence of transradial coronary angiography and intervention in China: Report from the Transradial coronary intervention Registration Investigation in China (TRI-China). <i>International Journal of Cardiology</i> , 2010, 145, 246-247.	1.7	15
231	Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease. <i>Circulation</i> , 2009, 119, 2040-2050.	1.6	38
232	Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: Comparison with bare-metal stent implantation. <i>American Heart Journal</i> , 2008, 155, 553-561.	2.7	37
233	Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent. <i>Chinese Medical Journal</i> , 2008, 121, 492-7.	2.3	1
234	A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients. <i>Chinese Medical Journal</i> , 2006, 119, 533-8.	2.3	0